Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy‐induced peripheral neurotoxicity: Systematic review and directions for future research

Abstract

Chemotherapy-induced peripheral neurotoxicity (CIPN) diagnosis is largely based on patient reported outcomes. Wearables, sensors, and smart devices may potentially provide early detection and monitoring of CIPN. We systematically reviewed data on wearables, sensors, and smart devices to detect and/or monitor signs and symptoms of CIPN. Moreover, we provide directions and recommendations for future studies.A literature search using PubMed/MEDLINE, Web of Science, IEEE Xplore, and CINHAL databases was conducted from database inception until March 2021.The search was further updated in July 2022 to ensure currency of results. A total of 1885 records were title-abstract screened, 33 full texts were assessed, and 16 were included. The retrieved papers were heterogeneous in terms of study design, sample size, CIPN severity, chemotherapy agents, type of wearable/sensor/device applied, parameters of interest, and purpose. Data are promising and provide preliminary evidence on wearables, sensors, and smart devices for CIPN detection and monitoring.There are several issues and knowledge gaps that should be addressed. We propose a framework for future studies.

Considerations for establishing and maintaining international research collaboration: the example of chemotherapy-induced peripheral neurotoxicity (CIPN)—a white paper

“…From this perspective, biomarkers (e.g., neurofilament light chain [NfL]) represent a promising higher-sensitivity proxy of early damage [ 20 ], even before neurotoxic symptoms arise. Further, in selected settings, innovative tools, such as wearables, sensors, and other telemedicine devices, might be explored as secondary outcome measures to record surrogate measures of toxicity at home, avoiding frequent outpatient visits [ 21 ]. Lastly, logistical considerations are required; neurotoxicity assessments may be difficult to access in resource-limited settings and should be planned to minimize participant burden.…”

Relationship between chemotherapy-induced peripheral neuropathy and physical activity in cancer survivors: A prospective longitudinal study

“…Research using wearable devices for patients with CIPN has been conducted for early diagnosis screening, 14 , 15 assessing the relationship between activity and sleep quality during and after treatment for one year, 16 and measuring balance abnormalities. 14 , 17 However, many of these studies used relatively short-term measurements, typically lasting from a few days to one week.…”

“…Research using wearable devices for patients with CIPN has been conducted for early diagnosis screening, 14 , 15 assessing the relationship between activity and sleep quality during and after treatment for one year, 16 and measuring balance abnormalities. 14 , 17 However, many of these studies used relatively short-term measurements, typically lasting from a few days to one week. 16 , 17 Since drugs like oxaliplatin and paclitaxel show significant changes in CIPN around 2–3 days after administration, 4 measuring long-term physical activity to elucidate changes during the course of treatment is of great significance.…”

Advances in Non-Electrochemical Sensing of Human Sweat Biomarkers: From Sweat Sampling to Signal Reading

“…Fresh and abundant sweat is a prerequisite for accurate measurement by sensors. In the early days, sweat was collected by tying gauze to the skin, and the collected sweat was centrifuged and analyzed using desktop equipment [31][32][33]. This method was laborious and time consuming.…”